APA (7th ed.) Citation

BL, K., JM, S., JM, K., D, K., A, S., J, E., . . . TB, P. (2024). Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression. JCO precision oncology, 8, e2300686. https://doi.org/10.1200/PO.23.00686

Chicago Style (17th ed.) Citation

BL, Kong, et al. "Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression." JCO Precision Oncology 8 (2024): e2300686. https://doi.org/10.1200/PO.23.00686.

MLA (9th ed.) Citation

BL, Kong, et al. "Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression." JCO Precision Oncology, vol. 8, 2024, p. e2300686, https://doi.org/10.1200/PO.23.00686.